Therefore, we can conclude that under tumor conditions, CDKN2A faces epigenetic modifications to hinder its expression and only CDKN2A with loss-of-function mutations is highly expressed in the tumor tissue and that collectively results in a poor clinical outcome. The gene discussed is CDKN2A; the disease is neoplasm.